Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 3;30(11):9710-9733.
doi: 10.3390/curroncol30110705.

Multiple Myeloma in 2023 Ways: From Trials to Real Life

Manlio Fazio  1 , Vittorio Del Fabro  2 , Nunziatina Laura Parrinello  2 , Alessandro Allegra  3 , Uroš Markovic  2 , Cirino Botta  4 , Fabrizio Accardi  5 , Iolanda Donatella Vincelli  6 , Salvatore Leotta  2 , Federica Elia  2 , Benedetta Esposito  1 , Bruno Garibaldi  1 , Gabriele Sapuppo  1 , Alessandra Orofino  1 , Alessandra Romano  7 , Giuseppe A Palumbo  8 , Francesco Di Raimondo  1   2   7 , Concetta Conticello  2
Affiliations
Review

Multiple Myeloma in 2023 Ways: From Trials to Real Life

Manlio Fazio et al. Curr Oncol. .

Abstract

Multiple myeloma is a chronic hematologic malignancy that obstinately tends to relapse. Basic research has made giant strides in better characterizing the molecular mechanisms of the disease. The results have led to the manufacturing of new, revolutionary drugs which have been widely tested in clinical trials. These drugs have been approved and are now part of the therapeutic armamentarium. As a consequence, it is essential to combine what we know from clinical trials with real-world data in order to improve therapeutic strategies. Starting with this premise, our review aims to describe the currently employed regimens in multiple myeloma and compare clinical trials with real-life experiences. We also intend to put a spotlight on promising therapies such as T-cell engagers and chimeric antigen receptor T-cells (CAR-T) which are proving to be effective in changing the course of advanced-stage disease.

Keywords: CAR-T cells therapy; autologous stem cell transplantation; bispecific antigens; daratumumab; frailty; minimal residual disease; multiple myeloma; real-life; relapsed-refractory disease; sequencing; standard of care.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no potential conflict of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Mateos M.-V., Weisel K., De Stefano V., Goldschmidt H., Delforge M., Mohty M., Cavo M., Vij R., Lindsey-Hill J., Dytfeld D., et al. LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36:1371–1376. doi: 10.1038/s41375-022-01531-2. - DOI - PMC - PubMed
    1. Wester R., Sonneveld P. Innovations in treatment and response evaluation in multiple myeloma. Haematologica. 2016;101:518–520. doi: 10.3324/haematol.2016.142737. - DOI - PMC - PubMed
    1. Harousseau J.-L., Avet-Loiseau H. Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy. J. Clin. Oncol. 2017;35:2863–2865. doi: 10.1200/JCO.2017.73.1331. - DOI - PubMed
    1. Kumar S., Paiva B., Anderson K.C., Durie B., Landgren O., Moreau P., Munshi N., Lonial S., Bladé J., Mateos M.-V., et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346. doi: 10.1016/S1470-2045(16)30206-6. - DOI - PubMed
    1. Takamatsu H., Yoroidaka T., Fujisawa M., Kobori K., Hanawa M., Yamashita T., Murata R., Ueda M., Nakao S., Matsue K. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Int. J. Hematol. 2019;109:377–381. doi: 10.1007/s12185-019-02615-z. - DOI - PubMed